Blair William & Co. IL decreased its holdings in Codexis, Inc. (NASDAQ:CDXS) by 18.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,027 shares of the biotechnology company’s stock after selling 12,274 shares during the quarter. Blair William & Co. IL owned 0.09% of Codexis worth $646,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in CDXS. Advisor Group Holdings Inc. bought a new stake in Codexis during the first quarter valued at about $36,000. HighMark Wealth Management LLC grew its stake in shares of Codexis by 849.3% during the 3rd quarter. HighMark Wealth Management LLC now owns 4,348 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 3,890 shares during the period. Nisa Investment Advisors LLC increased its holdings in Codexis by 199.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 4,340 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 2,890 shares in the last quarter. Bank of Montreal Can raised its stake in Codexis by 330.6% during the 2nd quarter. Bank of Montreal Can now owns 5,594 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 4,295 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Codexis by 40.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,809 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 2,550 shares during the period. Institutional investors own 88.48% of the company’s stock.
Shares of CDXS stock opened at $17.35 on Friday. The stock has a market cap of $1.03 billion, a P/E ratio of -49.57 and a beta of 0.88. Codexis, Inc. has a 52 week low of $8.43 and a 52 week high of $18.87. The company’s fifty day simple moving average is $14.12 and its two-hundred day simple moving average is $12.58.
CDXS has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, November 4th. TheStreet upgraded Codexis from a “d” rating to a “c-” rating in a research report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Codexis in a research note on Friday, August 7th. Finally, BidaskClub raised Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, October 14th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.33.
In related news, Director Bernard J. Kelley sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $14.00, for a total transaction of $35,000.00. Following the sale, the director now owns 211,136 shares of the company’s stock, valued at $2,955,904. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Dennis P. Wolf sold 10,000 shares of the stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $11.68, for a total transaction of $116,800.00. Following the transaction, the director now owns 61,129 shares of the company’s stock, valued at approximately $713,986.72. The disclosure for this sale can be found here. Insiders own 10.70% of the company’s stock.
Codexis, Inc discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Further Reading: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.